XTANDI® (enzalutamide) is a trusted and FDA-approved brand that specializes in providing effective treatment options for patients with castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC). With a strong heritage and a commitment to safety, XTANDI has become a leading choice for healthcare professionals in the field. The brand offers a range of resources and support for both patients and healthcare professionals.

For patients, there is a dedicated website with valuable information, while healthcare professionals can access important prescribing information and guidelines. XTANDI's mechanism of action is well-documented, and its efficacy is supported by clinical data in both mCSPC and CRPC. Safety is of utmost importance to XTANDI, and its safety profile is well-established.

While rare, seizures have been observed in a small percentage of patients, particularly those with predisposing factors. It is essential for healthcare professionals to be mindful of these risks and take appropriate precautions. Overall, XTANDI is a reliable brand that offers effective treatment options and comprehensive support for patients and healthcare professionals alike